European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Go back to European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV| Gilead Sciences (NASDAQ: GILD) | Delayed: 145.65 -0.99 (0.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.64 | 52 Week High | $108.63 | |||
| Open | $145.46 | 52 Week Low | $71.39 | |||
| Day High | $147.68 | P/E | 80.47 | |||
| Day Low | $145.00 | EPS | $1.81 | |||
| Volume | 4,582,410 | |||||
